Cholangiocarcinoma

Cholangiocarcinoma starts in the bile ducts, which carry bile from the liver toward the intestine. Intrahepatic disease starts inside the liver; perihilar disease develops where the main ducts leave it; distal disease occurs farther down the duct near the pancreas. Gallbladder cancer belongs to the wider biliary tract cancer family but has its own surgical pathway.

Blocked bile flow may cause yellow eyes or skin, dark urine, pale stools and itching. Intrahepatic tumors may instead present with abdominal discomfort, appetite loss or an imaging finding. These symptoms also occur in noncancerous disease. Primary sclerosing cholangitis, certain bile duct abnormalities and chronic liver or biliary disease increase risk, but many people have no recognized predisposing condition.

Contrast CT or MRI maps the tumor, blood vessels, lymph nodes and possible spread. MRCP shows the bile duct anatomy without inserting an endoscope. ERCP can obtain duct samples and relieve obstruction; a liver mass may require a different sampling route. The team should plan tissue collection with the intended treatment in mind, rather than treating every bile duct narrowing as the same problem.

For potentially operable perihilar or distal disease, discuss biopsy with the hepatobiliary team first. Needle sampling through the peritoneum can affect later treatment options, particularly transplant assessment. A negative brushing does not reliably exclude cancer. CA19-9 is supporting information: obstruction or inflammation may raise it, and some people do not produce it.

Fever or shaking chills with jaundice, worsening abdominal pain, confusion or marked weakness may signal cholangitis or sepsis and need urgent medical assessment. A blocked stent can cause similar problems even during otherwise effective cancer treatment.

Drainage may improve symptoms and liver tests enough to permit treatment. Its timing and route depend on infection, the obstruction and the planned operation. Not every patient going directly to surgery needs a preoperative stent. In perihilar disease, the team must decide which liver segments to drain; simply placing more stents is not necessarily better.

Potentially curative surgery aims to remove the cancer completely while leaving enough functioning liver and a safe bile drainage route. Intrahepatic tumors usually require liver resection; perihilar tumors may need bile duct and major liver resection; distal tumors often require a pancreaticoduodenectomy, also called a Whipple operation. The operation is determined by anatomy, not by the shared name ‘bile duct cancer’.

After recovery, adjuvant capecitabine is a reference option to discuss following resection. Margin status, lymph nodes, recovery and treatment tolerance matter. Radiation or chemoradiation is considered selectively, rather than automatically for everyone. Transplantation is a specialized pathway for highly selected patients, especially particular perihilar cases under strict protocols; an unresectable tumor does not automatically qualify.

For patients able to tolerate combination treatment, gemcitabine and cisplatin with durvalumab or pembrolizumab are established first-line approaches. The US approvals cover advanced biliary tract cancer and do not require a PD-L1-positive result for these chemotherapy combinations. They are different from biomarker-selected immunotherapy given alone.

Kidney function, hearing, neuropathy, infection and daily functioning affect whether cisplatin-based treatment is suitable. A less intensive approach may be preferable when toxicity would outweigh benefit. Imaging response, symptoms and liver tests are reviewed together. Selected patients whose disease becomes sufficiently limited can be reconsidered for surgery or local treatment by a specialist team.

In advanced disease, request a plan for molecular profiling before or during first-line therapy. Relevant results include FGFR2 fusions or rearrangements, IDH1 mutations, HER2, BRAF V600E and MSI/MMR, with broader panels able to assess rarer targets such as NTRK or RET fusions. Their frequency differs by location and pathology; testing should not be replaced by assumptions about the tumor’s site.

Ask whether the sample is sufficient, whether the assay detects gene fusions, and whether HER2 protein testing is included. A mutation, an amplification and a fusion are different findings. Tumor profiling also differs from inherited-risk testing; a potentially hereditary result may require a separate genetics assessment.

The following examples describe US indications for adults; availability and approved use must be checked in the country where treatment is planned. Pemigatinib and futibatinib approvals require an FGFR2 fusion or rearrangement, not any FGFR alteration. Their cholangiocarcinoma indications, and the biliary indication for zanidatamab, remain accelerated approvals requiring confirmation of benefit.

The newer zanidatamab combinations for stomach and esophageal adenocarcinoma have different eligibility rules. Their IHC 2+/ISH-positive option must not be transferred to the biliary indication.

Review the site of progression, previous benefit, adverse effects and molecular results before switching treatment. FOLFOX has randomized evidence after gemcitabine–cisplatin in patients well enough for further chemotherapy. The original trial preceded routine first-line immunotherapy, which is relevant when applying its results today. A matched targeted therapy or a clinical trial may be another option.

Liver-directed radiation, ablation or arterial treatments may help selected liver-limited cases, but they do not replace systemic assessment when disease has spread elsewhere. For HER2 IHC 3+ tumors, trastuzumab deruxtecan has a separate US accelerated solid-tumor indication after prior treatment when no satisfactory alternative remains. Its risk of interstitial lung disease makes new cough or breathlessness important to report promptly.

Keep the stent or drain record, including placement, exchanges and the contact for blockage or infection. Ask for help with itching, appetite loss, pain and weight loss early. Follow-up needs to consider both cancer recurrence and practical complications of biliary surgery or drainage. A rising tumor marker should be interpreted with scans and the possibility of obstruction or infection.

FGFR inhibitors need phosphate monitoring and scheduled eye assessment; vision changes require prompt contact. Ivosidenib needs attention to heart rhythm and interacting medicines. Bring the full medication list, not only cancer medicines, to each review.

• Pathology report, slides or blocks if available, and the exact primary site.
• Original CT/MRI files, operation and drainage reports, bilirubin and kidney function trends.
• Complete molecular reports and the dates, effects and toxicities of earlier treatment.